XASXVIT
Market cap29mUSD
Jan 10, Last price
0.08AUD
1D
-5.75%
1Q
-5.75%
IPO
-77.22%
Name
Vitura Health Ltd
Chart & Performance
P/E
13.58
P/S
0.39
EPS
0.01
Div Yield, %
11.40%
Shrs. gr., 5y
34.65%
Rev. gr., 5y
%
Revenues
124m
+5.56%
Net income
4m
-74.57%
CFO
7m
-27.92%
Dividend
Sep 04, 20230.01 AUD/sh
Earnings
Feb 24, 2025
Profile
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | 123,871 5.56% | 117,344 75.16% | 66,992 3,857.36% | |||||
Cost of revenue | 109,975 | 106,305 | 56,224 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 13,896 | 11,039 | 10,768 | |||||
NOPBT Margin | 11.22% | 9.41% | 16.07% | |||||
Operating Taxes | 1,314 | 6,304 | 3,732 | |||||
Tax Rate | 9.46% | 57.11% | 34.66% | |||||
NOPAT | 12,582 | 4,735 | 7,036 | |||||
Net income | 3,512 -74.57% | 13,809 128.31% | 6,049 -249.38% | |||||
Dividends | (5,438) | (5,463) | ||||||
Dividend yield | 11.10% | 1.86% | ||||||
Proceeds from repurchase of equity | 356 | (2,371) | ||||||
BB yield | -0.73% | 1.95% | ||||||
| Debt | ||||||||
Debt current | 1,726 | 666 | 489 | |||||
Long-term debt | 14,998 | 2,082 | 9,630 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 185 | 84 | 50 | |||||
Net debt | 4,604 | (16,472) | (6,556) | |||||
| Cash flow | ||||||||
Cash from operating activities | 6,997 | 9,708 | 13,505 | |||||
CAPEX | (329) | (928) | (377) | |||||
Cash from investing activities | (13,203) | (838) | 1,997 | |||||
Cash from financing activities | (1,295) | (6,099) | (1,504) | |||||
FCF | 15,295 | 1,139 | 3,028 | |||||
| Balance | ||||||||
Cash | 11,348 | 18,849 | 16,077 | |||||
Long term investments | 773 | 371 | 598 | |||||
Excess cash | 5,927 | 13,353 | 13,325 | |||||
Stockholders' equity | 38,444 | 34,902 | 26,075 | |||||
Invested Capital | 43,724 | 22,911 | 16,197 | |||||
ROIC | 37.76% | 24.21% | 77.86% | |||||
ROCE | 27.99% | 30.44% | 36.47% | |||||
| EV | ||||||||
Common stock shares outstanding | 569,927 | 571,785 | 486,868 | |||||
Price | 0.09 -83.30% | 0.52 106.00% | 0.25 138.10% | |||||
Market cap | 49,014 -83.36% | 294,469 141.93% | 121,717 188.59% | |||||
EV | 53,278 | 277,919 | 115,133 | |||||
EBITDA | 15,538 | 12,027 | 11,451 | |||||
EV/EBITDA | 3.43 | 23.11 | 10.05 | |||||
Interest | 1,047 | 34 | 441 | |||||
Interest/NOPBT | 7.54% | 0.31% | 4.10% | |||||